CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $11.39B, above the global median of $1.15B
- FinancialsAltman Z-Score 12.09: safe zone
- Interpretations5 currently firing — 1 · 4
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.44%Below 5Y avg (0.45%)
Annual Rate
USD 0.32Paid quarterly
Payout Ratio
27.6%Sustainable
Paying Dividends
14 yr
Last Ex-Dividend
Aug 24, 2026
Last Payment
Sep 4, 2026
Screen for this company's dividend patterns
Find other companies where the same dividend readings fire.
Long Dividend Streak With Three-Year FCF Coverage
→dividend consistency
dividend coverage and payment stability
ratio cashflow fcf conversion
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company return capital?
Long Dividend Streak With Three-Year FCF Coverage
Years of uninterrupted dividends, covered by free cash flow on a three-year average.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
The statements on file don't all cover the same year: income statement FY2026, balance sheet FY2025, cash-flow statement FY2025. Each figure below is labelled with the year it comes from.
Financials view
Market Capitalization
11.39BUSDvs all stocks (USD)
Trailing P/E
62.54xvs Biotechnology peers
Revenue (TTM)
1.22BUSDvs all stocks (USD)
Profit Margin
14.97%vs Biotechnology peers
Beta
1.27xvs all stocks
52-Week Change
38.88%vs all stocks
Forward Annual Dividend Yield
0.44%vs all stocks
Market Capitalization
11.39BUSDvs all stocks (USD)
Enterprise Value
11.41BUSDvs all stocks (USD)
Trailing P/E
62.54xvs Biotechnology peers
Forward P/E
31.45xvs Biotechnology peers
PEG Ratio
-0.1495xvs Biotechnology peers
Price to Sales (TTM)
9.36xvs Biotechnology peers
Price to Book (MRQ)
5.37xvs Biotechnology peers
Enterprise to Revenue
9.39xvs Biotechnology peers
Enterprise to EBITDA
34.15xvs Biotechnology peers
Gross Margin
65.82%vs Biotechnology peers
Profit Margin
14.97%vs Biotechnology peers
Operating Margin
27.87%vs Biotechnology peers
Return on Assets (TTM)
6.67%vs Biotechnology peers
Return on Equity (TTM)
9.03%vs Biotechnology peers
Revenue (TTM)
1.22BUSDvs all stocks (USD)
Revenue per Share (TTM)
7.79USDUpdated Sep 28, 2026Quarterly Revenue Growth
1.30%vs Biotechnology peers
Gross Profit (TTM)
804.88MUSDvs all stocks (USD)
EBITDA (TTM)
347.67MUSDvs all stocks (USD)
Net Income (TTM)
181.84MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
1.33%vs Biotechnology peers
Operating Cash Flow (TTM)
292.07MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
229.65MUSDvs all stocks (USD)
Forward Annual Dividend Rate
0.3200USDUpdated Sep 28, 2026Forward Annual Dividend Yield
0.44%vs all stocks
Trailing Annual Dividend Rate
0.3200USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.44%vs all stocks
5-Year Average Dividend Yield
0.45%vs all stocks
Payout Ratio
27.59%vs Biotechnology peers
Minority Interest (Equity)
0.00USDFY2025 · Jun 30, 2025Revenue
1.22BUSDFY2026 · Jun 30, 2026Cost of Goods Sold
415.97MUSDFY2026 · Jun 30, 2026Gross Profit
799.07MUSDFY2026 · Jun 30, 2026Operating Income
272.61MUSDvs all stocks (USD)
Pre-tax Income
240.68MUSDFY2026 · Jun 30, 2026Income Tax Expense
58.82MUSDFY2026 · Jun 30, 2026Net Income
181.86MUSDFY2026 · Jun 30, 2026EBIT
250.31MUSDFY2026 · Jun 30, 2026EBITDA (Income Statement)
375.99MUSDFY2026 · Jun 30, 2026Research & Development
94.77MUSDFY2026 · Jun 30, 2026Selling, General & Administrative
406.67MUSDFY2026 · Jun 30, 2026Non-operating Interest Income
4.22MUSDFY2026 · Jun 30, 2026Non-operating Interest Expense
9.63MUSDFY2026 · Jun 30, 2026EPS (Basic)
1.17USDFY2026 · Jun 30, 2026EPS (Diluted)
1.16USDFY2026 · Jun 30, 2026Basic Shares Outstanding
155.96MSharesFY2026 · Jun 30, 2026Diluted Shares Outstanding
155.96MSharesFY2026 · Jun 30, 2026Net Income from Continuing Operations
181.86MUSDFY2026 · Jun 30, 2026Preferred Stock Dividends
22.00KUSDFY2026 · Jun 30, 2026Operating Cash Flow
185.64MUSDFY2025 · Jun 30, 2025Free Cash Flow
154.64MUSDFY2025 · Jun 30, 2025Cash & Cash Equivalents (End of Period)
162.19MUSDFY2025 · Jun 30, 2025Income Tax Paid
74.36MUSDFY2025 · Jun 30, 2025Interest Paid
18.95MUSDFY2025 · Jun 30, 2025Starting Profit (CF Statement)
73.40MUSDFY2025 · Jun 30, 2025Depreciation & Amortization
109.90MUSDFY2025 · Jun 30, 2025Deferred Taxes (CF)
-51.11MUSDFY2025 · Jun 30, 2025Stock-based Compensation
40.83MUSDFY2025 · Jun 30, 2025Other Non-cash Items
2.11MUSDFY2025 · Jun 30, 2025Change in Accounts Receivable (CF)
42.60MUSDFY2025 · Jun 30, 2025Change in Accounts Payable (CF)
-13.95MUSDFY2025 · Jun 30, 2025Change in Other Assets/Liabilities
-18.14MUSDFY2025 · Jun 30, 2025Capital Expenditures
-31.01MUSDFY2025 · Jun 30, 2025Net Acquisitions
-15.00MUSDFY2025 · Jun 30, 2025Purchase of Investments
0.00USDFY2025 · Jun 30, 2025Sale of Investments
1.08MUSDFY2025 · Jun 30, 2025Other Investing Activity
2.45MUSDFY2025 · Jun 30, 2025Net Investing Cash Flow
-42.47MUSDFY2025 · Jun 30, 2025Long-term Debt Issuance
104.00MUSDFY2025 · Jun 30, 2025Long-term Debt Payments
-77.00MUSDFY2025 · Jun 30, 2025Common Stock Repurchase
-275.73MUSDFY2025 · Jun 30, 2025Common Dividends Paid
-50.39MUSDFY2025 · Jun 30, 2025Other Financing Charges
-6.52MUSDFY2025 · Jun 30, 2025Net Financing Cash Flow
-305.64MUSDFY2025 · Jun 30, 2025Shares Outstanding
156.10MSharesUpdated Sep 28, 2026Float Shares
156.16MSharesUpdated Sep 28, 2026Shares Short
6.63MSharesUpdated Sep 28, 2026Short Ratio
2.70daysvs all stocks
Short % of Shares Outstanding
4.82%vs all stocks
% Held by Insiders
0.33%vs all stocks
% Held by Institutions
115.12%vs all stocks
Total Cash (MRQ)
265.48MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.69USDUpdated Sep 28, 2026Total Debt (MRQ)
289.09MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1371xvs Biotechnology peers
Current Ratio (MRQ)
4.55xvs Biotechnology peers
Book Value per Share (MRQ)
13.51USDUpdated Sep 28, 2026Total Assets
2.56BUSDvs all stocks (USD)
Total Current Assets
608.30MUSDFY2025 · Jun 30, 2025Total Liabilities
639.06MUSDFY2025 · Jun 30, 2025Total Non-current Assets
1.95BUSDFY2025 · Jun 30, 2025Total Non-current Liabilities
463.21MUSDFY2025 · Jun 30, 2025Total Current Liabilities
175.85MUSDFY2025 · Jun 30, 2025Cash & Cash Equivalents
162.19MUSDFY2025 · Jun 30, 2025Other Short-term Investments
0.00USDFY2025 · Jun 30, 2025Accounts Receivable
206.88MUSDFY2025 · Jun 30, 2025Inventory
189.45MUSDFY2025 · Jun 30, 2025Accounts Payable
25.31MUSDFY2025 · Jun 30, 2025Short-term Debt
14.10MUSDFY2025 · Jun 30, 2025Deferred Revenue
32.57MUSDFY2025 · Jun 30, 2025Other Current Liabilities
1.65MUSDFY2025 · Jun 30, 2025Long-term Debt
429.96MUSDFY2025 · Jun 30, 2025Other Non-current Liabilities
27.08MUSDFY2025 · Jun 30, 2025Common Stock (Book)
1.55MUSDFY2025 · Jun 30, 2025Retained Earnings
1.07BUSDFY2025 · Jun 30, 2025Total Shareholders' Equity
1.92BUSDvs all stocks (USD)
52-Week Low
43.20USDUpdated Sep 28, 202652-Week High
72.69USDUpdated Sep 28, 202652-Week Change
38.88%vs all stocks
Beta
1.27xvs all stocks
50-Day MA
72.21USDUpdated Sep 28, 2026200-Day MA
61.72USDUpdated Sep 28, 2026Avg 10-Day Volume
3.24MSharesUpdated Sep 28, 2026Avg 30-Day Volume
2.70MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
1.16USDUpdated Sep 28, 2026Other Income / Expense
-26.52MUSDFY2026 · Jun 30, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Goodwill-Heavy Equity
Equity looks heavy for the industry, but much of it is goodwill from past acquisitions.
Reads
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Diagnostic
Underinvestment Cash Flow
Less of its cash flow goes to capex than at most of its peers, on an asset base already largely written down.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 12.09: safe zoneNotable
Altman Z-Score: 12.09
High earnings qualityNotable
Earnings Quality Score: 0.97
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $11.39B, above the global median of $1.15BNotable
Market cap (USD): 11,386,572,261Global Median: 1,150,342,212.262
Revenue is $1.22B, above the global median of $559.35MNotable
Revenue (USD): 1,215,038,976Global Median: 559,350,010.583
Levered free cash flow is $229.65M, above the global median of $18.98MNotable
Levered free cash flow (USD): 229,653,120Global Median: 18,979,762.15
Companies that share the same coordination system — how they create, deliver, or capture value.
Recordati Industria Chimica e Farmaceutica S.p.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pharmaron Beijing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingFlow
Dr. Reddy's Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bio-Rad Laboratories Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Haisco Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sichuan Kelun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bruker Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Masimo Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aurobindo Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Fosun Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Ametek Inc.
3 interpretationsHigh Retained Earnings With Profitability And EquityLong Dividend Streak With Three-Year FCF CoverageGoodwill-Heavy Equity
Evolution AB (publ)
2 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesGoodwill-Heavy Equity
Dover Corporation
3 interpretationsHigh Retained Earnings With Profitability And EquityLong Dividend Streak With Three-Year FCF CoverageGoodwill-Heavy Equity